Vigabatrin (Vigafyde)
Small molecule
Evidence outlook
Approved: Epilepsy, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
Its US label states: "The efficacy of VIGAFYDE is based upon a comparison of the compositional differences between vigabatrin for oral solution and VIGAFYDE oral solution."
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other GABA transaminase (GABA-T) drugs
Vigabatrin (Sabril). Compare all 2 GABA transaminase (GABA-T) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vigabatrin (Vigafyde): this drug | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.